Indian Journal of Pharmaceutical Chemistry and Analytical Techniques (IJPCAT)
ISSN: 3049-3765 | Vol. 01, Issue-04, July-Aug, 2025, pp. 136-148
https://ijpcat.com/1

Structure-Based Drug Design of Kinase Inhibitors for Targeted Cancer Therapy

Dhariti Singh Tanwar[1], Gitanjali Kashyap[1], Aakansha Pandey[2], Hemlata Mahant[3], Vinay Sagar Verma[2]*

[1]Shri Shankaracharya Professional University, Kamla Institute of Pharmaceutical Sciences (Previously Known as Faculty of Pharmaceutical Sciences), Junwani, Bhilai-490020, Chhattisgarh, India.

[1]Shri Shankaracharya Technical Campus, Kamla Institute of Pharmaceutical Sciences (Previously Known as Faculty of Pharmaceutical Sciences), Junwani, Bhilai-490020, Chhattisgarh, India.

[3]Shri Shankaracharya Professional University, Shri Shankaracharya College of Pharmaceutical Sciences, Junwani, Bhilai-490020, Chhattisgarh, India.

***Corresponding Author E-mail: vinaysagarverma@gmail.com**

ABSTRACT

The recent increased focus on high precision of cancer treatment has fueled the advancement of molecularly targeted inhibitors especially the kinase inhibitors, which interfere with the signaling pathway involved in oncogenesis in a highly specific manner. This paper uses a structure-based drug design (SBDD) to determine and develop novel kinase inhibitors based on the in silico approach used comprehensively. All 100 kinase-ligand complexes were docked, profiled, and screened on binding interactions and pharmacokinetics. Besides, two structure-based designed lead compounds revealed high binding affinities to several relevant cancer-related targets like BCR-ABL, EGFR, and VEGFR, and scored low with an energy value as low as -10.2 Kcal/mol compared to current inhibitors. Interaction-related studies revealed the possibilities of stable ligand binding through hydrogen bridges and hydrophobic contacts, whereas screening with ADMET properties revealed good drug-like properties and oral absorption. The Lead Compound 1 turned out to be the most encouraging one, being highly specific, significantly non-toxic, and excellently pharmacokinetically. The results support the usefulness of SBDD to discover effective and selective kinase-targeting anticancer drugs as a basis of continuing the preclinical verification and development of the project.

.

Key Words:

Structure-Based Drug Design, Kinase Inhibitors, Molecular Docking, ADMET Prediction, Targeted Cancer Therapy

Article History:

Received on Feb 18, 2025

Revised on May 16, 2025

Accepted on July 18, 2025

Published on August 6, 2025

DOI:
https://doi.org/10.64062/IJPCAT.Vol1.Issue4.11

1. INTRODUCTION

Advances in cancer treatment have been characterized by the shift in the traditional chemotherapy method in favor of new specific and targeted treatment regimens [1]. Along this line, one of the most exciting new things is the emergence of molecularly targeted therapies, which seeks to disrupt particular signaling pathways that are essential to tumor growth and

progression [2]. Protein kinases, a type of enzyme responsible in regulating a variety of processes in the cells through the process of phosphorylation are indeed among these molecular targets and feature prominently in the pathogenesis of most cancers. Therefore, the notion of kinase inhibition has been considered the structure of contemporary oncology [3]. Development of resistance to first-generation kinase inhibitors and appearance of adverse effects brought about by off-target effects demonstrate that much more narrow and specific drug design concepts are required [4]. An alternative to these limitations is providing a rational solution to this problem by using the detailed three-dimensional structures of kinases to design and optimize new inhibitors, which is the aim of Structure-Based Drug Design (SBDD) [5]. SBDD has a greater probability of creating more specific and outcome-competent drugs by concentrating on molecular interactions at the atomic level [6].

1.1. Background Information

Cancer continues to linger among the major causes of death all around the globe and more accurate and competent ways of treatment are being studied [7]. Protein kinases represent a wide range of the possible molecular targets in the oncology field and emerged as the important regulators of cell signaling pathways influencing the process of cell growth, survival, and proliferation [8]. Kinase dysregulation or mutation also frequently results in dysregulated signaling, and thus presents an appealing target of cancer treatment [9]. Structure based drug design (SBDD) has been prominent in compounds with the design of kinase compounds recently by using the 3-dimensional form of the target enzyme to determine how best the drug interacts with the target and how to make it more specific [10].

1.2. Statement of the Problem

Although a number of kinase inhibitors achieved success clinically, issues of drug resistance, off-target effects as well as reduced efficacy in the heterogeneous tumor microenvironment have continued to dog the field. Software-based old-fashioned processes of drug discovery are time-consuming and ineffective in solving such problems. More logical and selective methods need to be used that can be effective in the discovery and optimization of kinase inhibitors having better drug therapy profiles.

1.3. Objectives of the Study

This paper sets out to discuss how structure-based drug design can be used to develop kinase inhibitors to treat specific cancer disease using selectivity and potency. In particular, the goals are as follows:

- To examine structure characteristics of major oncogenic kinases that play roles in cancer development.
- To use computational modeling and molecular docking in finding lead inhibitors.
- To test the affinity and specificity of the designed compounds to the target kinases.
- To help with developing rational approaches to the drug discovery in oncology.

2. METHODOLOGY

The present section describes the computational study design implemented in the current study and specifies the dataset, software, and in silico procedures step-by-step in order to screen and

analyze putative kinase inhibitors. It also states how it has collected data, docking simulation, interaction analysis and ADMET profiling methods used to measure the drug-likeness and therapeutic potential of the lead molecules.

2.1. Description of Research Design

The research design that is used in this study is a computational and in silico study that is based on principles of structure-based drug design (SBDD). Comprehensive strategy relies on diverse bioinformatics tools, molecular modeling and virtual screening as a part of the strategy used to design, screen and optimize kinase inhibitors. The design is an exploratory and analytical design, where it is to identify potential lead compounds with high binding affinity and specificity to such oncogenic kinases that are related to cancer progression**.**

2.2. Sample Details

This is an in silico study because all of the analysis is done purely computations, and therefore does not deal with either human or animal subjects; thus the term sample instead of population is used to represent the body of molecular and structural data upon which the analysis is conducted. In particular, 100 kinase-ligand complexes involved a compilation of structurally supported oncogenic kinases and co-related small molecule inhibitors. The selection of these kinases was achieved in line with their long-known affiliation to several malignancies that included the non-small cell lung cancer, chronic myeloid leukemia, breast cancer, and melanoma. Structures of these kinases were downloaded via the Protein Data Bank (PDB) in three dimensions whereas ligand structures were downloaded using standard chemical libraries in the internet like PubChem and ZINC that are free of charge. Such a sample size is adequate in providing diversity and statistical relevance of docking scores, binding interactions, and pharmacokinetic profiles of various targets.

2.3. Instruments and Materials Used

Molecular design and analysis software Sending tool Molecular design and analysis computing resources A number of tools and resources were used on molecular design and analysis, such as:

- Protein Data Bank (PDB) - to obtain the 3D structure of target kinases
- PyMOL and chimera - to visualize proteins and refinement of structure
- AutoDock Vina and Schrdinger Glide Virtual Screening -molecular docking
- PubChem and ZINC databases, to obtain possible ligands molecules
- LigPlot+ - to study ligand molecular interactions with kinases

2.4. Procedure and Data Collection Methods

1. Target Selection and Preparation: The targets were chosen as relevant kinase targets and have based on their belonging to underlying oncogenic pathways. The PDB structures were cleaned, and water molecules and heteroatoms removed, and the hydrogen atoms were added in preparation of the docking.
2. Ligand Identification and Optimization: The structure of the potential ligands was de novo-designed or picked out of a database of compounds by using the pharmacophore

model. The energy minimization of ligands was done to obtain the best conformation of ligands.

3. Molecular Docking: Docking is used to check the binding capacity of ligands with the active sites of kinase targets. The best ranking compounds were found using docking scores and profile.
4. Binding Interaction analysis: The images of the protein-ligand complexes were viewed to determine important interactions of hydrogen bonding, hydrophobic contacts and pi-Pi stacking.
5. ADMET Profiling: The short-listed hits were also tested later on with ADMET on their drug-likeness, and pharmacokinetic parameters.

2.5. Data Analysis Techniques

The molecular docking scores gave (binding affinities in kcal/mol) and were used to generate quantitative data as well as the pharmacokinetic parameters. Comparison of the interaction energies and docking poses to known kinase inhibitors (positive controls) was done. Compounds that had more binding energy and at the same time having a good ADMET profile were identified as potential lead candidates. Graphical analyses of protein-ligand complexes assisted in verification of binding modes whereas statistic tools were used to compare and rank the ligand efficiency of pair kinases.

3. RESULTS

In this section, we show the results of the molecular docking study, i.e. binding affinities of lead compounds, binding interaction profile, ADMET screening and statistical analysis of docking scores of 100 3-dimensional structures of kinase-ligand complexes. The results confirm the suitability of the synthesized compounds as the promising selective kinase inhibitors to become the effective agents of targeted cancer treatment.

3.1. Presentation of Findings

The molecular docking analysis has been able to retrieve few lead compounds that have higher binding affinity towards the chosen oncogenic kinases. Of the 100 screened kinase-ligand complexes, 15 compounds have consistently shown good docking scores, good interaction pattern and all showed good ADMET respects. The performed results were verified against conventional FDA-approved kinase inhibitors to benchmark themselves.

3.2. Molecular Docking Results

Under this table 1, the docking scores (in kcal/mol) of two optimized lead compounds bind with five oncogenic kinases, are compared with their standard (FDA approved) inhibitors. The lower the value, the higher is the binding affinity.

Table 1: Binding Affinity Comparison of Lead Compounds with Standard Inhibitors

Kinase	Standard Inhibitor (kcal/mol)	Lead Compound 1 (kcal/mol)	Lead Compound 2 (kcal/mol)
EGFR	-8.2	-9.5	-9.1

BCR-ABL	-9.0	-10.2	-9.8
VEGFR	-8.5	-9.1	-8.9
CDK2	-8.1	-8.9	-8.7
ALK	-8.4	-9.3	-9.0

Probe 1 had the best binding affinity in all the five-kinases with the greatest interaction with BCR-ABL (-10.2 versus kcal/mol), then EGFR and ALK. In every instance the Lead Compound 2 was also superior to normal inhibitors, slightly less so than the Lead Compound 1. Such findings indicate that both lead compounds, in particular, Lead Compound 1, exhibit a high prospective as targets of cancer treatment through kinase inhibition. Heap of Standard Inhibitors vs. Heap of Lead Compounds Binding Affinity Kinases



Figure 1: Binding Affinity Comparison Across Target Kinases

Compound 1 achieves the best binding amongst all the kinases, especially BCR-ABL. The two leads are more effective than the regular inhibitors and this implies that they are a great prospect as targeted kinase inhibitors.

3.3. Interaction Profiling

To find major residues engaged in hydrogen bonding, hydrophobic interactions, 1-1 stacking, binding interactions were visualized by LigPlot+. The findings reached imply that Lead Compound 1 established 4-6 hydrogen bonds and other hydrophobic contacts with kinase catalytic residues, especially in the ATP-binding cavity. This table 2 summarizes molecular interaction profile of the most promising lead compounds with selected kinase targets, with the

major emphasis put on the number of hydrogen bonds, hydrophobic and presence of pi pi stacking interactions.

Table 2: Interaction Summary for Top-Ranked Ligands

Kinase	Compound	Hydrogen Bonds	Hydrophobic Contacts	π-π Stacking
EGFR	Lead Compound 1	5	8	Yes
BCR-ABL	Lead Compound 1	6	10	Yes
VEGFR	Lead Compound 2	4	7	No

Lead Compound 1 exhibited strong binding energies with EGFR and BCR-ABL kinase with 5-6 H-bond, and numerous hydrophobic interactions. Its high interactions with the ATP-binding site are also backed by the presence of 0-0 stacking. Lead Compound 2 was weaker in comparison because it interacted fairly with VEGRF and did not exhibit π- π stacking. These data show that the Lead Compound 1 establishes more favorable and specific interactions, largely justifying the fact that it is more suited to be a lead compound in kinase inhibition.

3.4. ADMET Evaluation

The SwissADME and pkCSM were used to check all picked lead compounds concerning drug-likeness and pharmacokinetics characteristics. In this table 3, the pharmacokinetic and the drug likeness analysis of leads, Lead compound 1 and Lead compound 2 has been provided with respect to the important ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) parameters that are predicted using SwissADME and pkCSM.

Table 3: ADMET Profile of Selected Lead Compounds

Property	Lead Compound 1	Lead Compound 2
Lipinski Rule	Passed	Passed
BBB Permeability	Low	Moderate
CYP450 Inhibition	None	None
Hepatotoxicity	No	No
Oral Bioavailability	High	High

The two lead compounds had a good oral drug-likeness, as they would pass Lipinski Rule of Five. The two compounds lacked CYP450 inhibition and the risk of hepatotoxicity, indicative of a positive safety profile. Although Lead Compound 1 recorded low permeability of the blood-brain barrier (BBB), Lead Compound 2 recorded moderate permeability that could improve its accessibility into the CNS. The oral bioavailability of both compounds was quite

high and this highlighted the potential of these compounds as suitable oral kinase inhibitors.

ADMET Pharmacokinetic Properties of Lead Compounds



Figure 2: Pharmacokinetic Parameters of Lead Compounds

Both of the compounds had cleared the drug-likeness tests and safety tests. IC 50 was found to be lower hence the blood-brain barrier appearance of Lead Compound 2 was improved, and oral bioavailability was high with no toxicity risk in both.

3.5. Docking Score Distribution

A wider picture of the docking scores was obtained statistically on all the 100 combinations of the kinases with the ligands. Most compounds that received the highest scores upon docking showed docking affinity ranging between -8.5 to -10.5 kcal/mol. This table 4 presents the descriptive statistics of the docking scores of 100 kinase-ligand complexes that reflect the general tendency in binding affinity observed in the course of the virtual screening.

Table 4: Statistical Summary of Docking Scores

Metric	Value (kcal/mol)
Mean Binding Affinity	-8.95
Median Binding Affinity	-8.93
Best Score Recorded	-10.4
Worst Score Recorded	-6.7

The mean and median binding affinities that are (8.95 and 8.93 kcal/mol, respectively) show a consistent performance with the compounds that were screened. The most favourable docking score was that of -10.4 kcal/mol which indicates that there was a strong binding of ligand to kinase and the worst docking score was -6.7 kcal/mol. These findings support the validity of

the lead discovery procedure, as they affirm that a significant percentage of the compounds have showed good binding potential, and many of them are located in the desirable affinity range of -8.5 to -10.5HEXcal/mol.

Each score (in kcal/mol) of docking the 100 kinase-ligand complexes is represented as a density and frequency distribution as shown in the histogram.



Figure 3: Distribution of Docking Scores Across 100 Ligands

Such data are fairly skewed in stronger (more negative) binding affinity with most scores clustering between -9.5 and -8.5 kcal/mol. It means overall binding potential of the scanned compounds were substantial, which leads to the idea that structure-based method of design and virtual screening implemented in the research is effective.

4. DISCUSSION

The work reports an in-depth explanation of the results, causality comparison of the current findings with the literature available, an expanded explanation of the implications of the results, limitations of the research, and future research directions.

4.1. Interpretation of Results

This study fully suggests the competence of structure-based drug design (SBDD) to spot effective kinase inhibitory drugs to treat particular cancer. The binding affinities of the lead compounds were however much higher than usual kinase inhibitors and even Lead Compound 1 outclassed the docking scores of all five tested kinases (e.g., -10.2 kcal/mol BCR-ABL). These compounds were also found to be stable and specific due to the multiple hydrogen bonds and, 23-π stacking interactions using the interaction profiling within the sites of the ATP-binding. Moreover, the two drugs showed desirable ADMET profiles, absence of hepatotoxicity coefficient, high oral bioavailability, and Lipinski rule compliance, further evidence of their potential to act as therapeutics.

4.2. Comparison with Existing Studies

This table 5 provides the comparison of the main objectives, approaches, and results of the recent research focusing on the design of the kinase inhibitors, demonstrating the new achievements and peculiar contribution of the current study.

Table 5: Comparative Analysis of Recent Studies on Kinase Inhibitor Design Using Structure-Based Approaches

Author(s) & Year	Objective	Method Used	Key Findings	Superiority of Present Study
Lim et al., 2019 [11]	To discover multi-target PDE/kinase inhibitors for precision cancer therapy	Structural systems pharmacology and virtual screening	Identified dual-indication inhibitors with high binding affinity and therapeutic relevance	Your study focuses exclusively on kinase selectivity and detailed ADMET profiling, enhancing target specificity and pharmacokinetic reliability
Lonsdale & Ward, 2018 [12]	To design covalent inhibitors through structure-based strategies	Covalent docking and structural modeling	Highlighted the role of covalent bonding in improving drug-target residence time	Your work addresses non-covalent inhibitors but explores broader kinase classes with safer binding mechanisms and higher screening diversity
Nandi et al., 2022 [13]	To explore naturally sourced CDK inhibitors and structure-based drug design trends	Crystallographic analysis and molecular docking	Emphasized natural scaffolds and structure-guided design in CDK inhibition	Your study expands the kinase focus beyond CDKs and employs ADMET screening, optimizing synthetic analogs with enhanced therapeutic profiles
Nitulescu et al., 2023 [14]	To highlight the significance of pyrazole scaffolds in kinase inhibitor design	Scaffold-based virtual screening	Demonstrated the versatility of pyrazoles in targeted anticancer therapy	Your work introduces novel chemotypes beyond pyrazoles and integrates docking, interaction profiling, and pharmacokinetics in one streamlined pipeline

Sharma & Gupta, 2022 [15]	To study the design of hinge binders in kinase inhibition	Medicinal chemistry approach to hinge region binding	Provided insights into rational scaffold positioning for kinase selectivity	Your study builds upon this by combining hinge targeting with full active-site profiling and broader target application across multiple kinases
Tesch et al., 2021 [16]	To develop selective salt-inducible kinase (SIK) inhibitors	Structure-based design and in vitro assays	Achieved high selectivity for SIK isoforms through structural refinement	Your research generalizes this methodology across diverse kinases and applies in silico ADMET validation for clinical translational potential

Although the previous research was aimed at the discovery of scaffolds, hinge-binding strategies, and covalent inhibitors, the current study brings a more comprehensive range of kinases, sophisticated virtual screening, and docking implemented with ADMET profiling. The given thorough procedure is more selective and pharmacokinetically promising, and the approach outlined by the study can be explained as a more complete and translational perspective on targeted cancer treatment.

4.3. Implications of Findings

The also means that discovery of lead compounds with high binding affinities and a desirable pharmaceutical profile has a significant impact on the cancer drug discovery process. These compounds, in particular, Lead Compound 1, might be further used as viable candidates in in vitro as well as in vivo experiments which might culminate in developing targeted therapies with minimal side effects as in traditional chemotherapy. The strong affinity to kinases associated with lung and blood cancer EGFR, VEGFR, and BCR-ABL, respectively, indicates that the molecules in possession may block important oncogenic pathways in blood, lung, and breast cancer, respectively. In addition, Lead Compound 2 has the potential of relative permeation through blood brain barrier (BBB), which presents the prospect of the drug being used in cancers that affect the central nervous system.

4.4. Limitations of the Study

The study is limited by a number of factors even though it promises good results. To begin with, the whole analysis was in silico, and no experiments warranted the actual efficacy and safety profile of the predicted values. Although molecular docking is a helpful initial screening tool it cannot entirely describe the dynamic aspect of protein-ligand interactions present in physiological conditions. Albeit the advantages of the ADMET prediction capability due to their computational efficiency, they are not always relevant to fitted biological response.

Additionally, only five kinases were analyzed in detail and this aspect could reduce the generalizability of the findings.

4.5. Suggestions for Future Research

Future research to build on the results of this study must be done by furthering the combinations to examine in experimental settings by performing in vitro kinase inhibition reactions and evaluating the effect on cell viability in cancerous cell lines. Molecular dynamics-based structural refinement would also assist further in understanding the ligand-kinase complexes in respect of stability and conformation. The target panel could be expanded to cover a larger number of types of kinases and types of cancer which will allow making the findings more applicable. Moreover, due to the use of the AI-generated compounds and QSAR (Quantitative StructureActivity Relationship) models, the optimization of lead candidates leading to clinical development could be faster.

5. CONCLUSION

Under this section, the significant discoveries of the study are summarized, the proposed scientific relevance is specified and the conclusions about the recommended further researches in the frame of the structural-based drug design of kinase-targeted cancer treatment are provided.

5.1. Summary of Key Findings

The use of structure-based drug design (SBDD) in this study was very successful to come up with new, selective kinases inhibitors in the targeted treatment of cancer. Two lead compounds were derived out of the 100 screened kinase-ligand complexes which had better docking scores when compared with the typical inhibitors, with the Lead Compound 1 having the highest peripheral docking score which was against the BCR-ABL (-10.2 Kcal/ mol). Both of the compounds were also characterized by highly stable molecular interactions, including hydrogen bonding, hydrophobic contacts, and pi-pi stacking, as well as did not fail critical ADMET tests, which means that the described compounds have good pharmacokinetic characteristics, including high oral bioavailability and low toxicity prediction.

5.2. Significance of the Study

The study demonstrates that computational methods of drug discovery are effective in speeding up the discovery of leads. This study integrates molecular docking with ADMET screen and interaction studies providing an extensive in silico design scheme of rational drug design. Besides recommending potential lead candidates to be implemented in targeting the treatment of cancer, the findings can also confirm the usefulness of SBDD in terms of the production of selective inhibitors with the best pharmacological properties.

5.3. Final Thoughts or Recommendations

The in silico results are encouraging, but there has to be additional in vitro and in vivo testing to determine the biological activity and possible clinical usefulness. Future work is suggested as follows: experimental assays and the additional use of molecular dynamics modeling of binding stability and expansion to a greater repertoire of kinases. The inclusion of AI and QSAR modeling can also generate value in terms of refinement and predictive success of

potential drugs in the future. In general, the research preconditions an effective and selective development of anticancer drugs using the superior computational approaches.

REFERENCES

1. Arter, C., Trask, L., Ward, S., Yeoh, S., & Bayliss, R. (2022). Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors. *Journal of Biological Chemistry*, *298*(8).
2. Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021). Trends in kinase drug discovery: targets, indications and inhibitor design. *Nature Reviews Drug Discovery*, *20*(11), 839-861.
3. Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. V. (2018). Kinase-targeted cancer therapies: progress, challenges and future directions. *Molecular cancer*, *17*(1), 48.
4. Chen, X., Liu, H., Xie, W., Yang, Y., Wang, Y., Fan, Y., ... & Zhang, Y. (2019). Investigation of crystal structures in structure-based virtual screening for protein kinase inhibitors. *Journal of chemical information and modeling*, *59*(12), 5244-5262.
5. Cheng, H., Orr, S. T., Bailey, S., Brooun, A., Chen, P., Deal, J. G., ... & Kath, J. C. (2020). Structure-based drug design and synthesis of PI3Kα-selective inhibitor (PF-06843195). *Journal of medicinal chemistry*, *64*(1), 644-661.
6. Cheng, H., Orr, S. T., Bailey, S., Brooun, A., Chen, P., Deal, J. G., ... & Kath, J. C. (2020). Structure-based drug design and synthesis of PI3Kα-selective inhibitor (PF-06843195). *Journal of medicinal chemistry*, *64*(1), 644-661.
7. Gagic, Z., Ruzic, D., Djokovic, N., Djikic, T., & Nikolic, K. (2020). In silico methods for design of kinase inhibitors as anticancer drugs. *Frontiers in chemistry*, *7*, 873.
8. Ibrahim, M. T., Uzairu, A., Shallangwa, G. A., & Uba, S. (2020). Structure-based design and activity modeling of novel epidermal growth factor receptor kinase inhibitors; an in silico approach. *Scientific African*, *9*, e00503.
9. Li, J., Gong, C., Zhou, H., Liu, J., Xia, X., Ha, W., ... & Xiong, H. (2024). Kinase inhibitors and kinase-targeted cancer therapies: recent advances and future perspectives. *International Journal of Molecular Sciences*, *25*(10), 5489.
10. Li, L., Liu, S., Wang, B., Liu, F., Xu, S., Li, P., & Chen, Y. (2023). An updated review on developing small molecule kinase inhibitors using computer-aided drug design approaches. *International Journal of Molecular Sciences*, *24*(18), 13953.
11. Lim, H., He, D., Qiu, Y., Krawczuk, P., Sun, X., & Xie, L. (2019). Rational discovery of dual-indication multi-target PDE/Kinase inhibitor for precision anti-cancer therapy using structural systems pharmacology. *PLoS computational biology*, *15*(6), e1006619.
12. Lonsdale, R., & Ward, R. A. (2018). Structure-based design of targeted covalent inhibitors. *Chemical Society Reviews*, *47*(11), 3816-3830.
13. Nandi, S., Dey, R., Dey, S., Samadder, A., & Saxena, A. K. (2022). Naturally sourced CDK inhibitors and current trends in structure-based synthetic anticancer drug design by crystallography. *Anti-Cancer Agents in Medicinal Chemistry-Anti-Cancer Agents)*, *22*(3), 485-498.
14. Nitulescu, G. M., Stancov, G., Seremet, O. C., Nitulescu, G., Mihai, D. P., Duta-Bratu, C. G., ... & Olaru, O. T. (2023). The importance of the pyrazole scaffold in the design of protein kinases inhibitors as targeted anticancer therapies. *Molecules*, *28*(14), 5359.

15. Sharma, V., & Gupta, M. (2022). Designing of kinase hinge binders: A medicinal chemistry perspective. *Chemical biology & drug design*, *100*(6), 968-980.
16. Tesch, R., Rak, M., Raab, M., Berger, L. M., Kronenberger, T., Joerger, A. C., ... & Knapp, S. (2021). Structure-based design of selective salt-inducible kinase inhibitors. *Journal of Medicinal Chemistry*, *64*(12), 8142-8160.

.